Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +3.30%65 EBIT per Share is $-3.28 as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 163 Medical Diagnostics & Research companies, GeneDx Holdings ranks better than 94.48% on this metric.
GeneDx Holdings's EBIT per Share for the
three
months ended in Jun. 2026 was $-0.58.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.28.
During the past 12 months, the average EBIT per Share Growth Rate of GeneDx Holdings was -1268.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 78.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 66.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for GeneDx Holdings's EBIT per Share or its related term are showing as below:
WGS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -120.3 Med: 59.4 Max: 81.5
Current: 78.3
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of GeneDx Holdings was 81.50% per year. The lowest was -120.30% per year. And the median was 59.40% per year.
WGS's 3-Year EBIT Growth Rate is ranked better than 94.48% of 163
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.6
vs WGS: 78.30
GeneDx Holdings's EBIT for the
three
months ended in Jun. 2026 was $-17.1 Mil.
GeneDx Holdings (NAS:WGS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
GeneDx Holdings EBIT per Share Related Terms
GeneDx Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.28
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings (WGS) has a EBIT per Share of $-3.28 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on GeneDx Holdings and its competitors. According to the industry distribution chart, GeneDx Holdings ranks #9 out of 163 companies in the Medical Diagnostics & Research industry, placing it in the top 5.5%.
Is GeneDx Holdings' EBIT per Share too high?
GeneDx Holdings' current EBIT per Share is $-3.28. Based on the distribution chart, GeneDx Holdings ranks #9 out of 163 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' EBIT per Share compare to NEO and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #9 out of 163 companies for EBIT per Share. This places GeneDx Holdings in the top 6% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.60, based on 163 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on GeneDx Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current EBIT per Share is $-3.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current EBIT per Share is $-3.28. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current EBIT per Share is $-3.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
EBIT per Share: $-3.28
GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score
Get the complete analysis for WGS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
